Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.40 |
| ▸ | HMGCR | P04035 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28035577 | 1.00 | TSHR (0.52) | TSHRLMNAALDH1A1PTPN7HMGCR | |
| SCHEMBL7795312 | 0.92 | TSHR (0.56) | TSHRLMNAALDH1A1KMT2ACA12 | |
| SCHEMBL13892956 | 0.82 | TSHR (0.54) | TSHRLMNAALDH1A1PTPN7HMGCR | |
| SCHEMBL10794247 | 0.81 | TSHR (0.67) | TSHRLMNAALDH1A1PTPN7HMGCR | |
| SCHEMBL10794256 | 0.81 | TSHR (0.67) | TSHRLMNAALDH1A1PTPN7HMGCR | |
| SCHEMBL8596453 | 0.81 | TSHR (0.52) | TSHRLMNAALDH1A1PTPN7HMGCR | |
| SCHEMBL8411340 | 0.81 | PTPN7 (0.63) | TSHRLMNAALDH1A1PTPN7HMGCR | |
| SCHEMBL12910845 | 0.81 | TSHR (0.52) | TSHRLMNAALDH1A1PTPN7HMGCR | |
| SCHEMBL3129143 | 0.81 | PTPN7 (0.63) | TSHRLMNAALDH1A1PTPN7HMGCR | |
| SCHEMBL10403786 | 0.81 | PTPN7 (0.63) | TSHRLMNAALDH1A1PTPN7HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722910-B2 | Diyne compositions | EVOLVA AG (CH) | 2014-05-13 | — | — | US | disclosed |
| EP-2563769-A1 | DIYNE COMPOSITIONS | EVOLVA AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| US-20120196822-A1 | Diyne Compositions | EVOLVA AG (CH) | 2012-08-02 | — | — | US | disclosed |
| WO-2011134538-A1 | DIYNE COMPOSITIONS | EVOLVA LTD (CH) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196822-A1 | Diyne Compositions | OSR1, ERG28, OSBPL3 | TSHR 4613/4885LMNA 4321/4885ALDH1A1 3833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.